This chapter will discuss the rationale for genetic homogeneity and monitoring, the history of genetic monitoring from its inception to today, and current and historical means by which this may be accomplished.
Within the limitations of a preclinical study, our data provide another rationale for genetic testing and clinical alertness in LQT patients to identify those with sodium channel mutations, in order to start or maintain sodium channel blocker therapy.
In spite of the strong rationale for a role of genetic variants in Osterix influencing bone mass acquisition, we are not aware of any previous genetic studies in humans highlighting this association.
Therefore, we are not suggesting that the current finding be used as a rationale to reduce the counselling component of genetic counselling.
As Clayton and McKeigue [ 102] state, "The rationale for setting up cohort studies of genetic effects on disease risk is based on the argument that, because cohort studies can measure environmental exposures before disease onset, they are better than the case control design for study of gene-environment interactions.
We review the rationale behind and discuss methods of design and analysis of genetic association studies.
The rationale is that, even without phenotypic information, one can use patterns of genetic variation to highlight genomic regions under selection.
These results provide a rationale for the utilization of NAMPT inhibitors in cancers with this type of genetic background.
The rationale for testing such agents in ovarian disease is the high rate of genetic or epigenetic abnormalities found in the HR pathway and observed in EOC (including BRCA1 and BRCA2 genes in approximately 50% of cases) [59].
Thus, there has been a strong rationale for developing genomic resources that can be used to increase the rate of genetic improvement for milk and meat production, disease resistance, feed efficiency and reproductive performance.
